Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer.
Phase II study of Margolimab in combination with nab-paclitaxel in the first line setting in patients with metastatic triple negative breast cancer who are negative for PD-L1 expression. Novel immunotherapy approach targeting macrophage check point.
The primary objective of this study for the Safety Run-In Cohort is to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with nab-paclitaxel or paclitaxel in metastatic triple-negative breast cancer (mTNBC).
The primary objective of this study for the Randomized Cohorts is to evaluate the efficacy of magrolimab in combination with nab-paclitaxel or paclitaxel in solid tumors as determined by progression-free survival (PFS) by investigator assessment.
Inclusion/Exclusions: ECOG: 0-1. Must be PD-L1 negative. Stable brain metastasis allowed. No prior tx w/CD47 or signal regular targeting agents. No HIV, HBC, or HCV.
Learn More at clinicaltrials.gov
To participate please call: 310-582-7448